A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

NCT ID: NCT01146990

Last Updated: 2022-05-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

245 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-11-09

Study Completion Date

2020-08-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the continuing efforts to understand the benefits and risks of in utero exposure to 17P this study is designed to evaluate differences in developmental outcomes of children, aged 23 to 25 months, born to mothers who participated in the 17P Efficacy Trial sponsored by Hologic (Protocol number 17P-ES-003).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be a prospective, noninterventional follow-up study designed to provide a developmental assessment of children born to mothers who participated in the 17P Efficacy Trial. When subjects reach an age of 23 months after adjustment for gestational age, they will be screened for developmental delay using the 24 month ASQ version 3. Subjects who score positive (fall below the specified cut-off) for developmental delay in 1 or more domains will be referred for the 24 month Bayley Scales of Infant and Toddler Development (3rd edition, Bayley-III) and a neurological examination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Infants Born to Mothers in the 17P-ES-003 Study

Infants Born to Mothers Who Participated in the 17P-ES-003 Study and whose mothers consented for them to be followed for this study.

ASQ-3, Bayley III, Neurologic exam

Intervention Type DRUG

Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ASQ-3, Bayley III, Neurologic exam

Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Maternal enrollment which resulted in a live birth in the 17P Efficacy Trial: A Multi-center, Randomized, Double-blind Study of Hydroxyprogesterone Caproate Injection, 250 mg/mL, Versus Vehicle for the Prevention of Preterm Birth in Women With a Previous Singleton Spontaneous Preterm Delivery.

2\. During their involvement in the above protocol, mothers must have received at least one dose of study drug (Safety population).

3\. Children between 22 and 25 months of age adjusted for gestational age.

Exclusion Criteria

* 1\. There is no parent/legal guardian available to sign an informed consent. 2. Born to women who are unblinded to study group assignment.
Minimum Eligible Age

22 Months

Maximum Eligible Age

25 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Registrat-Mapi

OTHER

Sponsor Role collaborator

AMAG Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Drug Research Analysis Corp

Montgomery, Alabama, United States

Site Status

Watching Over Mothers and Babies Foundation

Tucson, Arizona, United States

Site Status

Grossmont Center for Clinical Research

La Mesa, California, United States

Site Status

Naval Medical Center San Diego

San Diego, California, United States

Site Status

Women's Associates

Colorado Springs, Colorado, United States

Site Status

Tripler Army Medical Center

Honolulu, Hawaii, United States

Site Status

The Women's Clinic

Boise, Idaho, United States

Site Status

Women's Healthcare Associates dba Rosemark WomenCare Specialists

Idaho Falls, Idaho, United States

Site Status

University of Louisville School of Medicine

Louisville, Kentucky, United States

Site Status

Women's Care Physicians/Obstetrical Specialists, PLLC

Louisville, Kentucky, United States

Site Status

Steven Z Lenowitz, MD, LLC

Bel Air, Maryland, United States

Site Status

Saginaw Valley Medical Research Group, LLC/Women's OB GYN, PC

Saginaw, Michigan, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Lyndhurst Gynecologic Associates

Winston-Salem, North Carolina, United States

Site Status

Triad Research Partners, LLC

Winston-Salem, North Carolina, United States

Site Status

SC Clinical Research Center, LLC

Columbia, South Carolina, United States

Site Status

Women's Physician Group

Memphis, Tennessee, United States

Site Status

Practice Research Organization, Inc.

Dallas, Texas, United States

Site Status

Wilford Hall Medical Center

Lackland Air Force Base, Texas, United States

Site Status

Tanner Clinic

Layton, Utah, United States

Site Status

Central Utah Clinic, Division of Mt. Timpanogos Women's Health Care

Pleasant Grove, Utah, United States

Site Status

Salt Lake Women's Center, PC

Sandy City, Utah, United States

Site Status

Naval Medical Center

Portsmouth, Virginia, United States

Site Status

Madigan Army Medical Center

Tacoma, Washington, United States

Site Status

The Ottawa Hospital

Ottawa, Ontario, Canada

Site Status

Medicine Professional Corporation Obstetrics and Gynaecology

Windsor, Ontario, Canada

Site Status

Fakultni nemocnice Hradec Králové

Hradec Králové, , Czechia

Site Status

Fakultní Nemocnice Ostrava

Ostrava, , Czechia

Site Status

Szegedi Tudományegyetem Szülészeti és Nogyógyászati Klinika

Szeged, Csongrád megye, Hungary

Site Status

Petz Aladár Megyei Oktató Kórház

Győr, Győr-Moson-Sopron, Hungary

Site Status

Debreceni Egyetem Orvos és Egészségtudományi Centrum, Szülészeti és Nogyógyászati Klinika

Debrecen, Hajdú-Bihar, Hungary

Site Status

Jósa András Oktatókórház Egészségügyi Szolgáltató Nonprofit Kft.

Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary

Site Status

Kazan State Medical University

Kazan', , Russia

Site Status

Krasnoyarsk State Medical University named after Prof. V.F.Voino-Yasenetsky

Krasnoyarsk, , Russia

Site Status

State Educational Institution Saint Petersburg I.I. Mechnikov State Medical Academy of RosZdrav

Saint Petersburg, , Russia

Site Status

Hospital Vall d'Hebrón

Barcelona, , Spain

Site Status

Hospital Universitario Puerta Del Mar

Cadiz, , Spain

Site Status

Hospital Universitario Materno Infantil de Canarias

Las Palmas de Gran Canaria, , Spain

Site Status

Hospital Universitario La Fe, Servicio de Neonatologia

Valencia, , Spain

Site Status

Institute of Pediatrics, Obstetrics and Gynecology of the Academy of Medical Sciences of Ukraine

Kiev, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Czechia Hungary Russia Spain Ukraine

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17P-FU-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Repeat Antenatal Steroids Trial
NCT00015002 TERMINATED PHASE3